Biocompatibility Parameters with Standard and Increased Dose of Citrate in Hemodialysis—A Randomized Trial
Open Access
- 4 July 2021
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (13) , 2987
Abstract
Background: The dose of citrate needed in regional citrate anticoagulation (RCA) to achieve optimal biocompatibility is unknown. We performed a randomized trial comparing two doses (ACTRN12613001340729). Methods: In 30 patients a single hemodialysis with either standard (2.7 mmol/L) or increased dose of citrate (4 mmol/L) was performed. C5a-desArg, myeloperoxidase (MPO), thrombin-antithrombin complex (TAT), and platelet factor 4 (PF4) were measured and the inner surface of the dialyzer fibers was evaluated with scanning electron microscopy (SEM). Results: A good separation of anticoagulation effect was achieved (post-filter ionized calcium 0.20 vs. 0.31 mmol/L, p < 0.05). There was no effect of citrate dose on any of the biocompatibility parameters; transient and parallel increase in PF4 after 30 min and parallel increase in TAT after 4 h were observed. There were no visually detected clotting problems within the circuit and no significant hypocalcemia in either group. SEM clotting score was excellent and comparable in both groups (p = 0.59). Conclusions: Given the excellent results in both groups, absence of between group differences and inability of the increased dose of citrate to completely blunt the small residual increase in PF4 and TAT, we conclude that the standard dose of citrate seems sufficient in RCA for chronic hemodialysis.Keywords
This publication has 24 references indexed in Scilit:
- Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopeniaKidney International, 2012
- Correction of Plasma Concentrations for Effects of Hemoconcentration or HemodilutionASAIO Journal, 2012
- Biocompatible Characteristics of High-Performance Membranes2011
- Long‐Term Citrate Anticoagulation in Chronic Hemodialysis PatientsTherapeutic Apheresis and Dialysis, 2011
- Platelets and the immune continuumNature Reviews Immunology, 2011
- Evaluation of Three Different Methods to Prevent Dialyzer Clotting Without Causing Systemic Anticoagulation EffectArtificial Organs, 2011
- Citrate Anticoagulation Control by Ionized Calcium Levels Does Not Prevent Hemostasis and Complement Activation During HemodialysisArtificial Organs, 2007
- Myeloperoxidase as a Marker of Hemodialysis Biocompatibility and Oxidative Stress: The Underestimated Modifying Effects of HeparinAmerican Journal of Kidney Diseases, 2006
- Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysisNephrology Dialysis Transplantation, 2005
- Effect of anticoagulation on blood membrane interactions during hemodialysisKidney International, 1999